Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus VIVLODEX.
ANSAID vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category C
Category C
NSAID
NSAID